FHTX · NASDAQ
Foghorn Therapeutics (FHTX) Stock Price & Fundamentals
Foghorn Therapeutics (FHTX) closed at $476.82 on Oct 9, 2026, up 0.33% from the previous close of $475.23.
Share price, past year
1Y +29.98%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $476.82 |
| Sep 30, 2026 | $474.35 |
| Aug 31, 2026 | $450.56 |
| Jul 31, 2026 | $422.03 |
| Jun 30, 2026 | $382.28 |
| May 29, 2026 | $368.42 |
| Apr 30, 2026 | $388.12 |
| Mar 31, 2026 | $363.31 |
| Feb 27, 2026 | $376.92 |
| Jan 30, 2026 | $371.60 |
| Dec 31, 2025 | $385.62 |
| Nov 28, 2025 | $364.53 |
| Oct 31, 2025 | $361.49 |
Key statistics
- Market cap
- $28.00B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.99
- Revenue (TTM)
- $36.74M
- Net income (TTM)
- −$64.58M
- Shares outstanding
- 58.7M
- Dividend yield
- —
- 52-week range
- $353.68 – $477.64
Foghorn Therapeutics's market cap is $28.00B, based on a share price of $476.82 and 58.7M shares outstanding as of Jun 30, 2026.
Financials
Foghorn Therapeutics reported revenue of $30.91M for fiscal 2025, up 36.75% from fiscal 2024.
Foghorn Therapeutics reported a net loss of $74.28M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $30.91M | +36.8% | −$74.28M | −240.3% | −$1.18 | −$86.15M |
| FY2024ended Dec 31, 2024 | $22.60M | −33.8% | −$86.62M | −383.2% | −$1.58 | −$101.31M |
| FY2023ended Dec 31, 2023 | $34.16M | +77.6% | −$98.43M | −288.2% | −$2.34 | −$119.33M |
| FY2022ended Dec 31, 2022 | $19.23M | +1,357.8% | −$108.88M | −566.3% | −$2.62 | $192.40M |
| FY2021ended Dec 31, 2021 | $1.32M | +206.7% | −$101.32M | −7,681.6% | −$2.73 | −$53.56M |
| FY2020ended Dec 31, 2020 | $430.00K | — | −$68.80M | −16,000.0% | −$6.23 | −$47.47M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $16.07M | −$7.19M | −$0.10 |
| Q1 FY2026ended Mar 31, 2026 | $3.27M | −$19.88M | −$0.29 |
| Q4 FY2025ended Dec 31, 2025 | $9.25M | −$21.66M | −$0.35 |
| Q3 FY2025ended Sep 30, 2025 | $8.15M | −$15.85M | −$0.25 |
| Q2 FY2025ended Jun 30, 2025 | $7.56M | −$17.94M | −$0.28 |
| Q1 FY2025ended Mar 31, 2025 | $5.95M | −$18.83M | −$0.30 |
| Q4 FY2024ended Dec 31, 2024 | $2.86M | −$19.50M | −$0.23 |
| Q3 FY2024ended Sep 30, 2024 | $7.81M | −$19.12M | −$0.31 |
Company profile
- Name
- Foghorn Therapeutics Inc.
- Ticker
- FHTX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 500 Technology Square, Suite 700, Cambridge, MA 02139
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001822462
Recent SEC filings
- Oct 1, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jun 24, 2026
- May 7, 2026
- May 7, 2026
- Apr 21, 2026
- Mar 11, 2026
Frequently asked questions
What is Foghorn Therapeutics's stock price?
Foghorn Therapeutics (FHTX) closed at $476.82 on Oct 9, 2026, up 0.33% from the previous close of $475.23.
What is Foghorn Therapeutics's market cap?
Foghorn Therapeutics's market cap is $28.00B, based on a share price of $476.82 and 58.7M shares outstanding as of Jun 30, 2026.
How much revenue does Foghorn Therapeutics make?
Foghorn Therapeutics reported revenue of $30.91M for fiscal 2025, up 36.75% from fiscal 2024.
Does Foghorn Therapeutics pay a dividend?
Foghorn Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Foghorn Therapeutics Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures